Samjin’s pyrimidinediones to enter Phase I clinical trials
Published: 2008-12-30 06:04:00
Updated: 2008-12-30 06:04:00
Samjin Pharmaceutical, in collaboration with their drug development partner, the US based ImQuest Pharmaceutical Inc., have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance.
It is believed that these compounds will prol...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
